142 related articles for article (PubMed ID: 29668748)
1. MDR-TB patients in KwaZulu-Natal, South Africa: Cost-effectiveness of 5 models of care.
Loveday M; Wallengren K; Reddy T; Besada D; Brust JCM; Voce A; Desai H; Ngozo J; Radebe Z; Master I; Padayatchi N; Daviaud E
PLoS One; 2018; 13(4):e0196003. PubMed ID: 29668748
[TBL] [Abstract][Full Text] [Related]
2. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
3. Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa.
Loveday M; Wallengren K; Brust J; Roberts J; Voce A; Margot B; Ngozo J; Master I; Cassell G; Padayatchi N
Int J Tuberc Lung Dis; 2015 Feb; 19(2):163-71. PubMed ID: 25574914
[TBL] [Abstract][Full Text] [Related]
4. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care.
Brust JC; Shah NS; Scott M; Chaiyachati K; Lygizos M; van der Merwe TL; Bamber S; Radebe Z; Loveday M; Moll AP; Margot B; Lalloo UG; Friedland GH; Gandhi NR
Int J Tuberc Lung Dis; 2012 Aug; 16(8):998-1004. PubMed ID: 22668560
[TBL] [Abstract][Full Text] [Related]
5. Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa.
Schnippel K; Rosen S; Shearer K; Martinson N; Long L; Sanne I; Variava E
Trop Med Int Health; 2013 Jan; 18(1):109-16. PubMed ID: 23170876
[TBL] [Abstract][Full Text] [Related]
6. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa.
Heller T; Lessells RJ; Wallrauch CG; Bärnighausen T; Cooke GS; Mhlongo L; Master I; Newell ML
Int J Tuberc Lung Dis; 2010 Apr; 14(4):420-6. PubMed ID: 20202299
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia.
Alemayehu S; Yigezu A; Hailemariam D; Hailu A
PLoS One; 2020; 15(7):e0235820. PubMed ID: 32716915
[TBL] [Abstract][Full Text] [Related]
8. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003.
Brust JC; Gandhi NR; Carrara H; Osburn G; Padayatchi N
Int J Tuberc Lung Dis; 2010 Apr; 14(4):413-9. PubMed ID: 20202298
[TBL] [Abstract][Full Text] [Related]
9. Cost-optimization in the treatment of multidrug resistant tuberculosis in Nigeria.
Musa BM; John D; Habib AG; Kuznik A
Trop Med Int Health; 2016 Feb; 21(2):176-82. PubMed ID: 26610176
[TBL] [Abstract][Full Text] [Related]
10. Household context and psychosocial impact of childhood multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa.
Loveday M; Sunkari B; Master I; Daftary A; Mehlomakulu V; Hlangu S; Marais BJ
Int J Tuberc Lung Dis; 2018 Jan; 22(1):40-46. PubMed ID: 29297424
[TBL] [Abstract][Full Text] [Related]
11. Association between health systems performance and treatment outcomes in patients co-infected with MDR-TB and HIV in KwaZulu-Natal, South Africa: implications for TB programmes.
Loveday M; Padayatchi N; Wallengren K; Roberts J; Brust JC; Ngozo J; Master I; Voce A
PLoS One; 2014; 9(4):e94016. PubMed ID: 24718306
[TBL] [Abstract][Full Text] [Related]
12. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa?
Pooran A; Pieterson E; Davids M; Theron G; Dheda K
PLoS One; 2013; 8(1):e54587. PubMed ID: 23349933
[TBL] [Abstract][Full Text] [Related]
13. Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa.
Loveday M; Wallengren K; Voce A; Margot B; Reddy T; Master I; Brust J; Chaiyachati K; Padayatchi N
Int J Tuberc Lung Dis; 2012 Feb; 16(2):209-15. PubMed ID: 22236922
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of decentralised care model for managing MDR-TB in India.
John D; Chatterjee P; Murthy S; Bhat R; Musa BM
Indian J Tuberc; 2018 Jul; 65(3):208-217. PubMed ID: 29933862
[TBL] [Abstract][Full Text] [Related]
15. Cost of multi drug resistance tuberculosis in Germany.
Diel R; Nienhaus A; Lampenius N; Rüsch-Gerdes S; Richter E
Respir Med; 2014 Nov; 108(11):1677-87. PubMed ID: 25443398
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of treating multidrug-resistant tuberculosis.
Resch SC; Salomon JA; Murray M; Weinstein MC
PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
[TBL] [Abstract][Full Text] [Related]
17. Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa.
Cox H; Ramma L; Wilkinson L; Azevedo V; Sinanovic E
Trop Med Int Health; 2015 Oct; 20(10):1337-45. PubMed ID: 25975868
[TBL] [Abstract][Full Text] [Related]
18. Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa.
Sinanovic E; Ramma L; Vassall A; Azevedo V; Wilkinson L; Ndjeka N; McCarthy K; Churchyard G; Cox H
Int J Tuberc Lung Dis; 2015 Feb; 19(2):172-8. PubMed ID: 25574915
[TBL] [Abstract][Full Text] [Related]
19. Cost-consequence analysis of ambulatory clinic- and home-based multidrug-resistant tuberculosis management models in Eswatini.
Peresu E; De Graeve D; Heunis JC; Kigozi NG
PLoS One; 2024; 19(4):e0301507. PubMed ID: 38564589
[TBL] [Abstract][Full Text] [Related]
20. Examining the cost of community-based tuberculosis treatment in South Africa.
Moran A; Kula N; Jagwer G; Broughton E; Pillay Y; Mvusi L; AlMossawi H; Ndjeka N; Mametja D; Dlamini C; Ahmedov S; Matji R; Kak N
Int J Tuberc Lung Dis; 2020 Jun; 24(6):612-618. PubMed ID: 32552992
[No Abstract] [Full Text] [Related]
[Next] [New Search]
